CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cardiff Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.89−0.02 (-1.71%)
Close on Oct 19, 2026
- Market cap
- $60.58M
- P/E (TTM)
- –
- Dividend yield
- –
Cardiff Oncology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Market Cap | $68.90M | $166.30M |
| Enterprise Value | $34.40M | $88.19M |
| PS Ratio | 135.64 | 3.65 |
| PB Ratio | 2.60 | 2.03 |
| P/TBV Ratio | 2.60 | 2.29 |
Enterprise value
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| EV / Sales | 67.72 | 2.51 |
Income (trailing twelve months)
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Revenue | $508.00K | $58.34M |
| Operating Income | -$42.27M | -$21.40M |
| Net Income | -$40.05M | -$22.46M |
| EBITDA | -$41.92M | -$16.91M |
| EPS (Diluted) | -$0.60 | -$0.83 |
Margins
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Operating Margin | -8320.1% | -44.0% |
| Profit Margin | -7884.1% | -40.2% |
| EBITDA Margin | -8251.0% | -30.2% |
Returns
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -94.1% | -53.2% |
| Return on Assets (ROA) | -70.8% | -40.9% |
| Return on Capital Employed (ROCE) | -159.3% | -38.1% |
Growth
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -6.96% | 5.96% |
| Revenue Growth (3Y CAGR) | 15.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 10.1% | 6.48% |
Balance sheet
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $34.50M | $61.43M |
| Net Cash (Debt) | $34.50M | $15.35M |
| Net Cash Per Share | $0.44 | $0.66 |
| Equity (Book Value) | $26.53M | $49.09M |
| Book Value Per Share | $0.34 | $1.37 |
| Tangible Book Value | $26.53M | $23.52M |
| Working Capital | $24.80M | $76.81M |
Financial position
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Current Ratio | 3.30 | 3.34 |
| Quick Ratio | 3.21 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Operating Cash Flow | -$40.85M | -$12.35M |
Efficiency
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.39 |
| Revenue Per Employee | $16.39K | $404.87K |
| Profits Per Employee | -$1.29M | -$703.34K |
| Employee Count | 31 | 74 |
Dividends and yields
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Earnings Yield | -58.1% | -23.3% |
Shares
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Shares Outstanding | 77,795,200 | 58,127,000 |
| Shares Change (YoY) | 15.8% | 10.9% |
| Shares Change (QoQ) | 0.19% | 0.54% |
| Float | 73,974,400 | 49,136,700 |
| Shares Held by Insiders | 4.91% | 11.6% |
| Shares Held by Institutions | 24.2% | 59.4% |
Scores
| Measure | Cardiff Oncology | Industry median |
|---|---|---|
| Altman Z-Score | -16.03 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Cardiff Oncology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.